AzTrials
AzTrials

HypotensionPhase 2ET-50-FentNCT01896960

ET50 With Fentanyl for Post Caesarean Section Spinal Hypotension

A Phase 2 study testing Bupivacaine with 15 micrograms of fentanyl in people with Hypotension and Pregnancy, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Hypotension is extremely common after induction of spinal anesthesia for cesarean delivery. Anesthetic blockade of the sympathetic outflow of the spinal cord causes vasodilation, and is one cause of this hypotension. The higher the spread of the blockade will result in a higher incidence of hypotension. Read more about this study

Who is it for?
Ages 18 to 50 years, women only
Conditions the study is for
Hypotension, Pregnancy
What is being tested?
Bupivacaine with 15 micrograms of fentanyl
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteCanada
Study dates
Jul 2013to Jun 2015
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients 18 years or older, presenting for scheduled cesarean delivery to the C7 birthing centre.

Who cannot join

  • Unable to communicate in English or French
  • Multiple gestations
  • Patients with hypertension
  • Patients with contraindications to any drug or techniques used in the study
  • BMI > 35

Trial locations and contacts

1 site in 1 country.

Aly Elbahrawy, MD contact

aly.elbahrawy@mail.mcgill.ca

Canada1 site, 1 recruiting
  • Royal Victoria Hospital

    Montreal, Quebec

    Albert Moore, MD, moore_albert@hotmail.com

    Recruiting

Other trials in Canada

About this study

Official title: The Time Required to Remain Sitting After Spinal Anesthesia With Fentanyl for 50% of Patients to Not Experience Hypotension.

Hypotension is extremely common after induction of spinal anesthesia for cesarean delivery. Anesthetic blockade of the sympathetic outflow of the spinal cord causes vasodilation, and is one cause of this hypotension. The higher the spread of the blockade will result in a higher incidence of hypotension. Injected hyperbaric medication has about 15 minutes to spread within the intrathecal space before it will be taken up by the nerve roots. The time that a patient remains in one position after medication injection will affect the spread of the resultant anesthetic block. A patient who is left sitting for a longer period of time after injection of hyperbaric medication will have a lower level of block than someone who is placed supine immediately. In this study, the investigators wish to use up down sequential analysis to determine the time period a patient should remain seated after intrathecal injection of hyperbaric bupivacaine and fentanyl that will result in a 50% rate of hypotension.

Read the detailed description

Up down sequential analysis is a method developed by Dixon to determine the point where 50% of people will have a positive response and 50% will have a negative response to an intervention. It is a very powerful technique that has been used to determine the median effective dose (referred to as ED50) of many medications. Using this method, patient number 1 is given a certain amount of the intervention being studied. If patient 1 has the desired response, patient 2 in the series is given less of the intervention, and if patient 1 does not have the desired response, patient 2 is given more of the intervention. This is repeated through a series of patients until the dose where there is a 50% response rate is determined. In this study, the investigators wish to use up down sequential analysis to determine the time period a patient should remain seated after intrathecal injection of hyperbaric medication that result in a 50% rate of hypotension, what we will call the ET50 (Estimated Time for 50% of patients to have hypotension). The investigators would like to explore this relationship with 2 clinically used doses of hyperbaric bupivicaine.

Patients scheduled for cesarean delivery arrive in the birthing centre 1-2 The patients will be given the same anesthetic care routinely used in the birthing centre, except that the investigators will control the time that the patient remains seated after injection of intrathecal hyperbaric bupivacaine. The baseline blood pressure and heart rate will be recorded. After intravenous access is obtained, an infusion of normal saline will be commenced at a rate of 100 cc per hour. The patient will be brought to the operating room, and the standard monitors will be placed. The intravenous fluid will be administered at a rate of 500 ml per hour for one hour. The patient will be placed in a sitting position. The landmarks of the spinal canal will be identified with an ultrasound, then using sterile technique, an epidural catheter will be placed in the L2-L3 spinal interspace, and then a 27 gauge whitacre needle will be used to access the intrathecal space at the L4-L5 spinal interspace. After identification of the intrathecal space, hyperbaric bupivacaine will be injected over 30 seconds. The patient will then be left in the sitting position for the predetermined time. The patient will then be placed supine, with a 15 degree wedge under the right hip. The noninvasive blood pressure will be set to measure the blood pressure every minute. Hypotension will be defined as a drop in blood pressure to more than 20% of the patient's preoperative blood pressure. The medications used for treatment of hypotension will be left to the discretion of the treating anesthesiologist. The height of the anesthetic blockade will be measured bilaterally with ice at 1, 5, 10, 15, and 20 minutes after the patient has been placed supine. If the block has not reached T6 by 20 minutes after the patient has assumed the supine position, or if the patient experiences any pain during the cesarean delivery, 5 ml of 2% lidocaine will be administered through the epidural catheter. If this does not suitably manage the pain, the treating anesthesiologist will be allowed to manage the pain as they see fit.

Determination of the time in the sitting position :

The study patient will be considered a success if the duration of time in the sitting position results in no pre-delivery hypotension. The study patient will be considered a failure if the time spent in the sitting position results in pre-delivery hypotension. A patient will be considered an indeterminate result if the ice test fails to show a block reaching T6 by 15 minutes. A patient following a success will be left in the sitting position for 15 seconds less than the preceding patient, and the patient following a failure will be left in the sitting position for 15 seconds more than the preceding patient. A patient following an indeterminate result will remain in the sitting position for the same time as the preceding patient. The first patient in the series will be left in the sitting position for two minutes and half for the 1.5 ml bupivacaine and 6 minutes and half for the 2 ml bupivacaine after the injection of the intrathecal medication.

Dosage determination and blinding:

To see if ET50 is dependent on the dosage of medication given, we will determine the ET50 for 2 doses of hyperbaric bupivicaine with 15 micrograms of fentanyl. Both of the doses we will study are used routinely in clinical practice. Using a computerized randomization schedule, we will randomly assign patients to receive either 2 ml or 1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg or 12.5 mg of bupivacaine respectively.

Recorded data:

The investigators will record the demographic data of the patient, including height, weight, age, gravidity, parity, weeks gestation, and reason for the cesarean delivery. The investigators will record the medical history of the patient, and medications that the patient takes. The investigators will record the admission heart rate, blood pressure and saturation. The investigators will record the time that the intrathecal medication is injected, and the time that that the patient remains seated after the spinal anesthesia has been commenced. The investigators will record the level of anesthetic blockade at 1,5,10,15,and 20 minutes after the patient has been placed supine. The investigators will record the blood pressure, and heart rate every minute after the patient has been placed supine until the baby has been delivered. The investigators will record any medications used to treat blood pressure before the baby has been born, and any medications used to treat breakthrough pain. The investigators will record the birth time, the baby gender, weight, apgar, and umbilical cord pH.

Being tested
Bupivacaine with 15 micrograms of fentanyl
Keywords
Post spinal hypotension, Cesarian Section, ET50, Bupivacaine, Fentanyl
Medical subject headings
Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine with 15 micrograms of fentanylDrug

    Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl

Study groups in NCT01896960
Study groupRoleWhat they receive
2 ml BupivacaineActive comparator2 ml Bupivacaine with 15 micrograms of fentanyl
Receives: Drug: Bupivacaine with 15 micrograms of fentanyl
1.5 ml BupivacaineActive comparator1.5 ml Bupivacaine with 15 micrograms of fentanyl
Receives: Drug: Bupivacaine with 15 micrograms of fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sitting time to avoid hypotension

    Sitting time required to avoid a drop of 20% of patient's baseline blood pressure or symptoms of hypotension in 50% of patients

    Measured: one hour

Secondary outcomes (1)
  1. Pain occurence

    Measured: One hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2013 (estimated)
  2. Study startJul 2013
  3. Primary completionJun 2015 (estimated)
  4. Study completionJun 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01896960
Sponsor's protocol ID
12-273-SDR
Acronym
ET-50-Fent
Status last verified
Jun 2014
First submitted
2 Jul 2013
Last updated
23 Jun 2014
Results posted
No
Data monitoring committee
No

Publications

  • Moore A, El-Mouallem E, El-Bahrawy A, Kaufman I, Moustafa M, Derzi S, Hatzakorzian R, Lipishan W. An up-down determination of the required seated duration after intrathecal injection of bupivacaine and fentanyl for the prevention of hypotension during Cesarean delivery. Can J Anaesth. 2017 Oct;64(10):1002-1008. doi: 10.1007/s12630-017-0931-z. Epub 2017 Jul 24.

    PubMed 28741272

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Bupivacaine with 15 micrograms of fentanyl in people with Hypotension and Pregnancy, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Aly Elbahrawy, MD (aly.elbahrawy@mail.mcgill.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sitting time to avoid hypotension (time frame: one hour). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01896960, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in